AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
GlobalData on MSN22h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsFailed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...
Addresses the significant threat of antimicrobial resistance.
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Hosted on MSN21h
The Antibiotic Arms Race: Can Science Stay Ahead of Rapidly Evolving Antibiotic-Resistant Bacteria?A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...
Infections by multidrug resistant organisms (MDROs) are a global health threat with a worrying increasing trend. In fragile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback